Table 2. Distribution of baseline covariates for all Medicare and commercial insurance enrollees in the TT prescription and PDE5I cohorts before and after weighting.
| Variable | TT Prescription | PDE5I Before Weighting | PDE5I After Weighting |
| N | 55,593 | 167,279 | 141,031 |
| Age, years | 54.4 | 56.0 | 54.3 |
| Medicare, % | 12.3 | 14.5 | 12.0 |
| Prior Diagnoses (ICD-9), % | |||
| Hyperlipidemia (272) | 26.5 | 23.5 | 26.3 |
| Hypertension (401–405) | 26.8 | 24.7 | 26.5 |
| Heart Disease (404,414,420–429) | 10.4 | 9.2 | 10.2 |
| Osteoarthritis (715,720–721) | 8.5 | 6.0 | 8.3 |
| Asthma (493,495) | 2.3 | 1.6 | 2.2 |
| Prior Prescriptions, % | |||
| Anticoagulant | 2.8 | 2.4 | 2.7 |
| Antiplatelets | 3.4 | 2.8 | 3.3 |
| Ace Inhibitors | 18.1 | 18.8 | 18.3 |
| Beta Blockers | 15.5 | 15.2 | 15.6 |
| Calcium Channel Blockers | 11.7 | 11.4 | 11.8 |
| Hypolipidemics | 37.0 | 33.7 | 36.7 |
| Anti-hypertensives NOS | 3.2 | 3.1 | 3.2 |
| Vasodialators | 2.0 | 1.3 | 1.9 |
| Other cardiac drugs | 13.8 | 11.5 | 13.6 |
| NSAIDs | 16.3 | 13.5 | 16.1 |
| SSRIs | 20.7 | 11.8 | 20.4 |
| Corticosteroids | 12.7 | 9.2 | 12.6 |
| Insulin | 3.9 | 2.9 | 3.9 |
| Diuretics | 10.4 | 9.9 | 10.4 |
| Anti-diabetes drugs | 15.2 | 12.7 | 15.0 |
The TT prescription patients were unweighted and the PDE5I patients were weighted to match the TT prescription cohort based on odds of TT prescription.